Toward imaging of alpha-synuclein with PET

Kejal Kantarci

doi:10.1016/j.cell.2023.06.018

Toward imaging of alpha-synuclein with PET

Kejal Kantarci

Radiology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment. Reporting in this issue of Cell, Xiang et al. developed a high-affinity positron emission tomography tracer for alpha-synuclein.

Original language	English (US)
Pages (from-to)	3327-3329
Number of pages	3
Journal	Cell
Volume	186
Issue number	16
DOIs	https://doi.org/10.1016/j.cell.2023.06.018
State	Published - Aug 3 2023

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2023.06.018

Cite this

@article{3fa9d8cc77aa43fe91bb9ec5629fa6c0,

title = "Toward imaging of alpha-synuclein with PET",

abstract = "Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment. Reporting in this issue of Cell, Xiang et al. developed a high-affinity positron emission tomography tracer for alpha-synuclein.",

author = "Kejal Kantarci",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = aug,

day = "3",

doi = "10.1016/j.cell.2023.06.018",

language = "English (US)",

volume = "186",

pages = "3327--3329",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "16",

}

TY - JOUR

T1 - Toward imaging of alpha-synuclein with PET

AU - Kantarci, Kejal

PY - 2023/8/3

Y1 - 2023/8/3

N2 - Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment. Reporting in this issue of Cell, Xiang et al. developed a high-affinity positron emission tomography tracer for alpha-synuclein.

AB - Development of radiopharmaceuticals for in vivo positron emission tomography imaging of alpha-synuclein aggregates has the potential to revolutionize Lewy body disease diagnosis and treatment. Reporting in this issue of Cell, Xiang et al. developed a high-affinity positron emission tomography tracer for alpha-synuclein.

UR - http://www.scopus.com/inward/record.url?scp=85166598194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85166598194&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2023.06.018

DO - 10.1016/j.cell.2023.06.018

M3 - Comment/debate

C2 - 37541192

AN - SCOPUS:85166598194

SN - 0092-8674

VL - 186

SP - 3327

EP - 3329

JO - Cell

JF - Cell

IS - 16

ER -

Toward imaging of alpha-synuclein with PET

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this